PHQ-9 Depression Screening for Adults with Diabetes

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider regarding any medical condition or treatment.

Key Takeaways

  • PHQ-9 is a brief 9-item self-report questionnaire screening for depression severity.
  • Depression is about 2x more common in adults with diabetes than general population.
  • ADA recommends depression screening at diabetes diagnosis and annually thereafter.
  • 0-4 minimal; 5-9 mild; 10-14 moderate; 15-19 moderately severe; 20-27 severe.
  • Depression worsens diabetes self-management and outcomes; treatment improves both.

The PHQ-9 (Patient Health Questionnaire-9) is a 9-item depression screening and severity measurement tool widely used in primary care. Format: self-administered questionnaire; takes 2-3 minutes; can be completed on paper, electronically, or verbally; each item asks about frequency of depression symptoms over the past 2 weeks. The 9 items match DSM diagnostic criteria for major depression: little interest or pleasure in doing things (anhedonia); feeling down, depressed, or hopeless; trouble falling asleep, staying asleep, or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself — failure or letting yourself or family down; trouble concentrating on things; moving or speaking so slowly others noticed, or being fidgety/restless; thoughts of being better off dead or hurting yourself. Each scored 0 (not at all) to 3 (nearly every day); total 0-27. Validated, freely available, no licensing fee. Depression and diabetes have bidirectional relationship with major consequences. Statistics: depression affects 15-30% of adults with type 2 diabetes (2x general population rate); depression often unrecognized in diabetes care. Impact: worse glycemic control (depression linked to higher A1C, more variability); worse self-management (less exercise, less medication adherence, less glucose monitoring); higher complication rates (heart disease, neuropathy, nephropathy); higher mortality (increased CV and all-cause mortality); worse quality of life; higher healthcare costs; increased risk for type 2 diabetes onset (in non-diabetic depressed individuals). Possible mechanisms: depression-related lifestyle factors (poor diet, inactivity, smoking); HPA axis dysregulation (cortisol elevation worsens insulin resistance); chronic inflammation; sleep disruption; effects of antidepressant medications on weight and glucose. ADA recommends screening at diabetes diagnosis and at least annually thereafter, plus during life changes and complications. Effective treatment improves both depression and diabetes outcomes. Scoring: sum item scores (0-3 each); total 0-27. Severity categories: 0-4 minimal depression (no treatment needed); 5-9 mild depression (watchful waiting; repeat in 2-4 weeks); 10-14 moderate depression (treatment plan; consider counseling, possible antidepressant); 15-19 moderately severe depression (active treatment); 20-27 severe depression (active treatment; consider specialist referral). Special considerations: Item 9 (suicidal thoughts) — ALWAYS triggers immediate attention regardless of total score; ask about suicide intent, plan, means; safety assessment; emergency evaluation if needed. PHQ-2 — shorter 2-item version (items 1-2); preliminary screen; if positive proceeds to full PHQ-9. Use over time: serial PHQ-9 tracks treatment response.

PHQ-9 Score Interpretation

Score Severity Action
0-4 Minimal No treatment
5-9 Mild Watchful waiting; lifestyle; repeat 2-4 weeks
10-14 Moderate Treatment plan; counseling and/or medication
15-19 Moderately severe Active treatment with medication and/or therapy
20-27 Severe Active treatment; consider specialist

Depression and Diabetes Statistics

Population Depression prevalence
General U.S. adults 7-10%
Adults with type 2 diabetes 15-30%
Adults with type 1 diabetes 10-20%
Women with diabetes About 25%
Adults with diabetes + complications 30-40%

Treatment Options for Diabetes-Comorbid Depression

  • Psychotherapy — CBT, behavioral activation, interpersonal therapy.
  • SSRIs — sertraline (Zoloft), escitalopram (Lexapro) — first-line generally.
  • SNRIs — duloxetine (Cymbalta) — also treats diabetic neuropathy.
  • Bupropion (Wellbutrin) — weight-neutral or weight loss; energy effect.
  • Avoid for weight gain — paroxetine (Paxil), mirtazapine (Remeron).
  • Combination therapy — medication + psychotherapy often more effective.
  • Exercise — proven antidepressant effect; also benefits diabetes.
  • Diabetes-specific cognitive behavioral therapy (CBT-D) — emerging evidence.
  • Address sleep disturbance.
  • Support groups (in-person or online).
  • Mindfulness-based approaches.
  • Refer to mental health specialist for severe or treatment-resistant depression.

The 9 PHQ-9 Items (Past 2 Weeks)

  • Little interest or pleasure in doing things.
  • Feeling down, depressed, or hopeless.
  • Trouble falling/staying asleep or sleeping too much.
  • Feeling tired or having little energy.
  • Poor appetite or overeating.
  • Feeling bad about yourself — failure or let yourself/family down.
  • Trouble concentrating (reading, watching TV).
  • Moving/speaking slowly or being fidgety/restless.
  • Thoughts of being better off dead or hurting yourself.

Suicide Safety Assessment

  • Item 9 positive (any score 1-3) — always assess further.
  • Ask directly: “Are you having thoughts of suicide?”
  • Assess: intent, plan, means, prior attempts.
  • Safety plan: remove access to means (firearms, medications).
  • Crisis resources: 988 Suicide and Crisis Lifeline.
  • Emergency department for active suicidal intent.
  • Inpatient psychiatric care if imminent danger.
  • Provider follow-up arranged before patient leaves.
  • Family/support person involvement.

The Bottom Line

The PHQ-9 (Patient Health Questionnaire-9) is a 9-item depression screening and severity measurement tool widely used in primary care. Format: self-administered questionnaire; takes 2-3 minutes; can be completed on paper, electronically, or verbally; each item asks about frequency of depression symptoms over the past 2 weeks. The 9 items match DSM diagnostic criteria for major depression: little interest or pleasure in doing things (anhedonia); feeling down, depressed, or hopeless; trouble falling asleep, staying asleep, or sleeping too much; feeling tired or having little energy; poor appetite or overeating; feeling bad about yourself; trouble concentrating; moving or speaking so slowly others noticed (or being fidgety/restless); thoughts of being better off dead or hurting yourself. Each scored 0 (not at all) to 3 (nearly every day); total 0-27. Validated, freely available, no licensing fee. Depression and diabetes have bidirectional relationship with major consequences. Statistics: depression affects 15-30% of adults with type 2 diabetes (2x general population rate); depression often unrecognized in diabetes care. Impact: worse glycemic control; worse self-management (less exercise, less medication adherence, less glucose monitoring); higher complication rates; higher mortality; worse quality of life; higher healthcare costs. Possible mechanisms: depression-related lifestyle factors; HPA axis dysregulation (cortisol elevation worsens insulin resistance); chronic inflammation; sleep disruption; effects of antidepressant medications on weight and glucose. ADA recommends screening at diabetes diagnosis and at least annually thereafter, plus during life changes and complications. Effective treatment improves both depression and diabetes outcomes. Severity categories: 0-4 minimal depression; 5-9 mild depression (watchful waiting; repeat in 2-4 weeks); 10-14 moderate depression (treatment plan); 15-19 moderately severe depression (active treatment); 20-27 severe depression (active treatment; consider specialist referral). Special considerations: Item 9 (suicidal thoughts) — ALWAYS triggers immediate attention regardless of total score; ask about suicide intent, plan, means; safety assessment; emergency evaluation if needed. Multiple effective treatment options: psychotherapy (CBT, behavioral activation, interpersonal therapy); SSRIs (sertraline, escitalopram) first-line generally; SNRIs (duloxetine — bonus for diabetic neuropathy pain); bupropion (weight-neutral or weight loss); avoid weight gain — paroxetine, mirtazapine; combination therapy often more effective; lifestyle approaches (regular exercise — proven antidepressant; sleep hygiene; social connection; mindfulness); diabetes management improving glycemic control may improve mood. Crisis resources: 988 Suicide and Crisis Lifeline for urgent help. Treatment works — most people improve. For adults with type 2 diabetes — ensure your provider screens at least annually with PHQ-9 or similar tool; if positive, follow through with treatment; depression treatment improves both quality of life and diabetes outcomes. See our broader diabetes complications guide for context.

Frequently Asked Questions

What is the PHQ-9?

The PHQ-9 (Patient Health Questionnaire-9) is a 9-item depression screening and severity measurement tool widely used in primary care. Format: self-administered questionnaire; takes 2-3 minutes; can be completed on paper, electronically, or verbally; each item asks about frequency of depression symptoms over the past 2 weeks. The 9 items match DSM diagnostic criteria for major depression: (1) Little interest or pleasure in doing things (anhedonia). (2) Feeling down, depressed, or hopeless. (3) Trouble falling asleep, staying asleep, or sleeping too much. (4) Feeling tired or having little energy. (5) Poor appetite or overeating. (6) Feeling bad about yourself — failure or letting yourself or family down. (7) Trouble concentrating on things. (8) Moving or speaking so slowly others noticed, or being fidgety/restless. (9) Thoughts of being better off dead or hurting yourself. Each scored 0 (not at all) to 3 (nearly every day); total 0-27. Validated, freely available, no licensing fee.

Why is depression screening important in diabetes?

Depression and diabetes have bidirectional relationship with major consequences. Statistics: depression affects 15-30% of adults with type 2 diabetes (2x general population rate); depression often unrecognized in diabetes care. Impact: (1) Worse glycemic control — depression linked to higher A1C, more variability. (2) Worse self-management — less exercise, less medication adherence, less glucose monitoring. (3) Higher complication rates — heart disease, neuropathy, nephropathy. (4) Higher mortality — increased CV and all-cause mortality. (5) Worse quality of life. (6) Higher healthcare costs. (7) Increased risk for type 2 diabetes onset (in non-diabetic depressed individuals). Possible mechanisms: (1) Depression-related lifestyle factors (poor diet, inactivity, smoking). (2) HPA axis dysregulation (cortisol elevation worsens insulin resistance). (3) Chronic inflammation. (4) Sleep disruption. (5) Effects of antidepressant medications on weight and glucose. ADA recommends screening at diabetes diagnosis and at least annually thereafter, plus during life changes and complications. Effective treatment improves both depression and diabetes outcomes.

How is the PHQ-9 scored and interpreted?

Simple total score with categories. Scoring: sum item scores (0-3 each); total 0-27. Severity categories: (1) 0-4 — minimal depression; no treatment needed. (2) 5-9 — mild depression; watchful waiting; repeat in 2-4 weeks; consider self-management strategies. (3) 10-14 — moderate depression; treatment plan; consider counseling, possible antidepressant, follow-up. (4) 15-19 — moderately severe depression; active treatment with pharmacotherapy and/or psychotherapy. (5) 20-27 — severe depression; active treatment; consider specialist referral; possible safety concerns. Special considerations: Item 9 (suicidal thoughts) — ALWAYS triggers immediate attention regardless of total score; ask about suicide intent, plan, means; safety assessment; emergency evaluation if needed. PHQ-2 — shorter 2-item version (items 1-2); preliminary screen; if positive proceeds to full PHQ-9. Use over time: serial PHQ-9 tracks treatment response; reduction of 5 points or to score below 5 indicates meaningful improvement. Not a diagnostic tool — positive screen requires clinical assessment to confirm major depression.

What if my PHQ-9 score suggests depression?

Multiple effective treatment options exist. Treatment approaches: (1) Psychotherapy — cognitive behavioral therapy (CBT), behavioral activation, interpersonal therapy; especially effective; can be combined with medications. (2) Antidepressant medication — SSRIs (sertraline/Zoloft, escitalopram/Lexapro, others) first-line; SNRIs (duloxetine/Cymbalta — bonus for diabetic neuropathy pain); bupropion (Wellbutrin — weight-neutral or weight loss). (3) Diabetes-specific considerations — some antidepressants cause weight gain (paroxetine/Paxil, mirtazapine/Remeron); some cause hypoglycemia (uncommon); SSRIs generally diabetes-friendly; duloxetine helpful if also have neuropathy. (4) Combination therapy — therapy + medication often more effective than either alone for moderate-severe depression. (5) Lifestyle approaches — regular exercise (proven antidepressant), sleep hygiene, social connection, sunlight exposure, mindfulness. (6) Diabetes management — improving glycemic control may improve mood. (7) Refer to mental health specialist for severe symptoms or treatment-resistant depression. (8) Crisis resources — 988 Suicide and Crisis Lifeline for urgent help. Treatment works — most people improve.

Sources

  1. Kroenke K, et al. The PHQ-9 Validity of a Brief Depression Severity Measure. J Gen Intern Med 2001.
  2. Anderson RJ, et al. The prevalence of comorbid depression in adults with diabetes. Diabetes Care 2001.
  3. American Diabetes Association. Standards of Medical Care in Diabetes — Psychosocial Care 2024.